for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

bluebird bio Inc

BLUE.O

Latest Trade

31.10USD

Change

2.98(+10.60%)

Volume

5,898,034

Today's Range

27.43

 - 

31.14

52 Week Range

24.24

 - 

76.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
28.12
Open
28.24
Volume
5,898,034
3M AVG Volume
37.70
Today's High
31.14
Today's Low
27.43
52 Week High
76.00
52 Week Low
24.24
Shares Out (MIL)
67.14
Market Cap (MIL)
1,888.01
Forward P/E
-2.32
Dividend (Yield %)
--

Next Event

bluebird bio Inc at Cowen Healthcare Conference (Virtual)

Latest Developments

More

Bluebird Bio Reports Q4 And Full Year 2020 Financial Results

Bluebird Bio Inc - Anticipates That Cash, Cash Equivalents, Marketable Securities Were About $1.3 Bln As Of December 31, 2020

Bluebird Bio To Separate Oncology Business Into Independent Company

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About bluebird bio Inc

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry

Biotechnology & Drugs

Contact Info

60 Binney St

CAMBRIDGE, MA

02142-1512

United States

+1.339.4999300

http://www.bluebirdbio.com

Executive Leadership

Daniel S. Lynch

Independent Chairman of the Board

Nick Leschly

President, Chief Executive Officer, Director

William D. Baird

Chief and Principal Financial Officer, Interim Principal Accounting Officer

Jason F Cole

Chief Operating Officer and Legal Officer, Secretary

Philip D. Gregory

Chief Scientific Officer

Key Stats

2.46 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.0K

2020

0.3K

2021(E)

0.1K
EPS (USD)

2018

-10.680

2019

-14.310

2020

-9.950

2021(E)

-11.355
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.53
Price To Book (MRQ)
1.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-40.16
Return on Equity (TTM)
-35.27

Latest News

Latest News

Bluebird bio plans to spin off cancer drugs unit

Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year to focus on rare genetic diseases, the company said on Monday.

Bluebird bio to spin off cancer drugs unit - WSJ

Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year, the Wall Street Journal reported on Monday.

Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies

Bluebird bio Inc <BLUE.O> said on Monday Bristol Myers Squibb Co <BMY.N> would give it a one-time payment of $200 million to buy out obligations for future royalties on sales outside the United States of two cancer therapies being developed by them.

Bristol Myers to pay $200 mln to Bluebird for royalty obligations

Bluebird bio Inc said on Monday partner Bristol Myers Squibb Co would pay $200 million to buy out future royalty obligations on sales of two therapies being developed by the companies.

BRIEF-Bluebird Bio Announces Amended Bcma Car-T Collaboration Agreement

* BLUEBIRD BIO ANNOUNCES AMENDED BCMA CAR-T COLLABORATION AGREEMENT

BRIEF-Bluebird Bio Says CEO Nick Leschly Reduced His Base Salary By Approximately 100% During This Twelve-Month Period

* BLUEBIRD BIO INC - NICK LESCHLY, CO'S CHIEF EXECUTIVE OFFICER, REDUCED HIS BASE SALARY BY APPROXIMATELY 100% DURING THIS TWELVE-MONTH PERIOD

BRIEF-Bluebird Bio Provides Assessment Of Impact Of COVID-19

* BLUEBIRD BIO PROVIDES ASSESSMENT OF IMPACT OF COVID-19, UPDATE ON BUSINESS OPERATIONS AND CLINICAL PROGRAM DEVELOPMENT

BRIEF-Bluebird Bio Unit And Apceth Biopharma GmbH Entered Into Amendment

* BLUEBIRD BIO - ON MARCH 6, CO'S UNIT AND APCETH BIOPHARMA GMBH ENTERED INTO AMENDMENT

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Bluebird prices gene therapy at 1.575 mln euros over five years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

Medigene broadens alliance on T-cell receptors with Bluebird Bio

German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31

* BLUEBIRD BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

BRIEF-Bluebird Bio Reports Q4 Loss Per Share $2.52

* BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up